Alvotech Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q3 2025 Performance:

Total revenues: $420 million for the first 9 months, reflecting a 24% year-on-year growth.

Q3 licensing revenues: $81 million, with a gross margin of 69%.

Adjusted EBITDA: $14 million (13% of revenues) for Q3; $68 million (16% margin) for the first 9 months.

Cash balance at the end of September: $43 million.

Revised Full-Year Guidance:

Revenue forecast lowered to $570 million - $600 million.

Adjusted EBITDA guidance revised to $130 million - $150 million.

2Strategic Updates and Business Highlights

Alvotech has launched its first two biosimilars and is expanding its pipeline, with 5 approved biosimilars and 12 additional programs in development.

The company has established a new operational base in Sweden to enhance R&D capabilities.

Alvotech is positioned to be a leader in the biosimilar market, targeting over $185 billion in originator markets.

Recent approvals for biosimilars to Simponi in Japan and the U.K., with EMA approval expected soon.

3Forward Guidance and Outlook

Anticipated growth of approximately 20% in 2025, with a compounded annual growth rate of 94% from 2021 to the end of 2025.

Expected strong finish to 2025, particularly in Q4, driven by new product launches and licensing revenues.

Management is focused on operational efficiencies and cost optimization to support future growth and margin recovery.

4Bad News, Challenges, or Points of Concern

Complete Response Letter (CRL): Received from the FDA regarding the BLA for the biosimilar to Simponi, primarily due to unresolved issues from an inspection of the Reykjavik facility.

The CRL has led to a revision of revenue expectations and potential delays in product launches.

Temporary loss in product revenues due to facility improvements and the need for operational adjustments.

Increased R&D spending impacting EBITDA margins, which decreased from 26% to 16% year-on-year.

5Notable Q&A Insights

Management clarified that the observations leading to the CRL were not repeat issues, and significant improvements have been made to the manufacturing processes.

There is confidence in resolving the FDA's concerns, with 93% of the commitments to address observations already completed.

Despite the CRL, interest in Alvotech's products remains strong, and the company is maintaining good relationships with commercial partners.

Future regulatory changes are seen as beneficial, allowing for faster development timelines for certain biosimilars, including Keytruda and Cimzia. Overall, while Alvotech faces challenges related to regulatory compliance and production adjustments, the company remains optimistic about its growth trajectory and market position in the biosimilar sector.